Bio-Techne Corporation

11/05/2024 | Press release | Distributed by Public on 11/05/2024 15:49

Statement of Changes in Beneficial Ownership - Form 4

Ownership Submission
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287 Estimated average burden hours per response... 0.5
(Print or Type Responses)
1. Name and Address of Reporting Person *
Geist William
2. Issuer Name and Ticker or Trading Symbol
BIO-TECHNE Corp [TECH] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
PRESIDENT, PROTEIN SCIENCES
(Last) (First) (Middle)
614 MCKINLEY PLACE NE 		3. Date of Earliest Transaction (Month/Day/Year)
11/01/2024
(Street)
MINNEAPOLIS, MN 55413 		4. If Amendment, Date Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4) 		7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/01/2024 M 9,912 A $ 0 14,351 D
Common Stock 11/01/2024 F 3,270 D $75.31 11,081 D
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5) 		6. Date Exercisable and Expiration Date
(Month/Day/Year) 		7. Title and Amount of Underlying Securities
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4) 		10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4) 		11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (1) (2) (2) Common Stock 3,320 3,320 D
Stock Options (Right to Buy) $100.39 (3) 02/01/2029 Common Stock 15,912 15,912 D
Performance Restricted Stock Units (1) (4) (4) Common Stock 7,140 7,140 D
Performance Stock Options (Right to Buy) $94.52 (4) (4) Common Stock 22,200 22,200 D
Stock Options (Right to Buy) $94.52 (5) 08/15/2029 Common Stock 29,600 29,600 D
Performance Restricted Stock Units (1) (6) (6) Common Stock 9,074 9,074 D
Performance Stock Options (Right to Buy) $84.61 (6) (6) Common Stock 24,424 24,424 D
Stock Options (Right to Buy) $84.61 (7) 08/15/2030 Common Stock 30,059 30,059 D
Restricted Stock Units (1) 11/01/2024 M 9,912 (8) (8) Common Stock 9,912 $ 0 9,911 D
Performance Restricted Stock Units (1) (9) (9) Common Stock 15,738 15,738 D
Restricted Stock Units (1) (10) (10) Common Stock 7,869 7,869 D
Stock Options (Right to Buy) $74.91 (11) 08/15/2034 Common Stock 21,204 21,204 D

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Geist William
614 MCKINLEY PLACE NE
MINNEAPOLIS, MN 55413 		PRESIDENT, PROTEIN SCIENCES

Signatures

/s/ Andrew Nick as Attorney-in-Fact for William Geist pursuant to Power of Attorney previously filed 11/05/2024
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
(2) 3,320 restricted stock units vest on 2/1/2025.
(3) Options to purchase 3,980 shares vest on each of 2/1/2023 and 2/1/2025, and options to purchase 3,976 shares vest on each of 2/1/2024 and 2/1/2026.
(4) Vests in full or in part on 8/15/2025 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
(5) Options to purchase 7,400 shares vest on each of 8/15/2023, 8/15/2024, 8/15/2025 and 8/15/2026.
(6) Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
(7) Options to purchase 7,515 shares vest on each of 8/15/2024, 8/15/2025, 8/15/2027, and 7,514 shares vest on 8/15/2026.
(8) 9,911 restricted stock units vest on 11/1/2025.
(9) Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
(10) 2,623 restricted stock units vest on each of 8/15/2025, 8/15/2026 and 8/15/2027.
(11) Options to purchase 5,301 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028.
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.